



RECEIVED

JUN 10 2002

TECH CENTER 1600/2900

Docket No.: 49,632 (71689)

RECEIVED

DEC 03 2001

TECH CENTER 1600/2900

TECH CENTER 1600/2900

SEP 10 2001

RECEIVED NOV 27 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pamela L. Zeitlin, et al. **EXAMINER:** Wang S.
SERIAL NO.: 09/523,776 **GROUP:** 1617
FILED: March 11, 2000
FOR: MODULATION OF PROTEIN EXPRESSION USING CARBOXYLIC
ARYL ALKENOIC ACID DERIVATIVES

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: August 30, 2001

By: Patricia A. Barnes
Patricia A. Barnes

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office action mailed June 5, 2001, Applicants provisionally elect Group I, i.e., Claims 15, 16 and 24 drawn to a method for treatment of cystic fibrosis, with traverse. Further elected with traverse is the compound 4-phenyl- Δ^3 -transbutenoic acid to satisfy the species election requirement.

REMARKS

Applicants respectfully request reconsideration of the Restriction Requirement.